- Home
- KIRK vs BOLD Comparison
KIRK vs BOLD Comparison
Compare KIRK & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIRK
- BOLD
- Stock Information
- Founded
- KIRK 1966
- BOLD 2018
- Country
- KIRK United States
- BOLD United States
- Employees
- KIRK N/A
- BOLD N/A
- Industry
- KIRK Diversified Commercial Services
- BOLD
- Sector
- KIRK Miscellaneous
- BOLD
- Exchange
- KIRK Nasdaq
- BOLD Nasdaq
- Market Cap
- KIRK 26.7M
- BOLD 24.4M
- IPO Year
- KIRK 2002
- BOLD 2024
- Fundamental
- Price
- KIRK $1.20
- BOLD $1.18
- Analyst Decision
- KIRK Buy
- BOLD Buy
- Analyst Count
- KIRK 2
- BOLD 3
- Target Price
- KIRK $4.50
- BOLD $4.00
- AVG Volume (30 Days)
- KIRK 146.9K
- BOLD 276.3K
- Earning Date
- KIRK 09-04-2025
- BOLD 08-11-2025
- Dividend Yield
- KIRK N/A
- BOLD N/A
- EPS Growth
- KIRK N/A
- BOLD N/A
- EPS
- KIRK N/A
- BOLD N/A
- Revenue
- KIRK $431,111,000.00
- BOLD N/A
- Revenue This Year
- KIRK N/A
- BOLD N/A
- Revenue Next Year
- KIRK N/A
- BOLD N/A
- P/E Ratio
- KIRK N/A
- BOLD N/A
- Revenue Growth
- KIRK N/A
- BOLD N/A
- 52 Week Low
- KIRK $1.05
- BOLD $1.00
- 52 Week High
- KIRK $2.50
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- KIRK 51.41
- BOLD N/A
- Support Level
- KIRK $1.15
- BOLD N/A
- Resistance Level
- KIRK $1.23
- BOLD N/A
- Average True Range (ATR)
- KIRK 0.04
- BOLD 0.00
- MACD
- KIRK 0.01
- BOLD 0.00
- Stochastic Oscillator
- KIRK 65.81
- BOLD 0.00
About KIRK Kirkland's Inc. COMMONSTOCK
Kirkland's Inc is a specialty retailer of home decor and gifts in the United States. The company stores provide various merchandise, including holiday decor, value pricing, and a stimulating in-store and online environment that provides customers with a brand experience. The company stores also offer an assortment of holiday merchandise in seasonal periods, as well as items that are suitable for gift-giving.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.